Dmitriy Zamarin, Chief, Gynecologic Medical Oncology; Co-Director, Center of Excellence for GYN Cancers at Icahn School of Medicine at Mount Sinai, shared Kelsey Monson’s post on LinkedIn, adding:
“This is arguably one of the most promising biomarkers for early detection of ovarian cancer that have been reported to date.
Uniquely, it explores a fundamental feature of the biology of pre-invasive and early invasive disease:
Something that appears to be less driven by cancer cell burden. This biomarker would be important to validate in larger cohorts, but certainly gives us hope that screening for early detection of ovarian cancer may be possible!”
Kelsey Monson, Postdoctoral Research Fellow, Tisch Cancer Institute at Icahn School of Medicine at Mount Sinai, shared:
“Honored to contribute a Nature Medicine News & Views article on an exciting new study of a potential new way to detect early and precancerous high-grade serous ovarian cancer.
Detecting the long noncoding RNA known as Tu-Stroma in the serum of women at risk of ovarian cancer represents a promising new circulating biomarker for detection at premalignant and early disease stages.
Virtually no detection methods exist for this stage of disease, so a simple, non-invasive biomarker like this could be highly impactful.”
Title: A novel candidate biomarker for detecting premalignant and early ovarian cancer
Authors: Kelsey Monson, Dmitriy Zamari
Title: Blood-based RNA biomarker for the early detection of ovarian cancer
Authors: Jochen Wilhelm, Amit Kumar…
You can also read: